Blood pressure: how to measure, manage, and treat high blood pressure (AMA #48 rebroadcast)

Episode Overview

• In this rebroadcast of a subscriber-exclusive AMA (funded entirely by premium memberships at peterattiamd.com/subscribe without paid ads, and intended for general informational purposes rather than medical practice), Dr. Peter Attia and co-host Nick Stenson explore the physiology, risks, measurement, and management of blood pressure.
• The episode breaks down how blood pressure functions as one of the three primary pillars of atherosclerotic cardiovascular disease (ASCVD) alongside smoking and apoB, detailing how chronically elevated pressure inflicts catastrophic mechanical damage on the heart, brain, and kidneys.
• Attia reviews landmark clinical research—including the SPRINT, SPRINT MIND, STEP, and Framingham studies—that shifted clinical guidelines to define normal blood pressure as strictly below 120/80 mmHg while highlighting the hazards of over-medicating into symptomatic hypotension.
• Listeners learn why single in-office blood pressure readings are notoriously unreliable, the exact sources of measurement error (including why automated cuffs can overestimate readings), how to differentiate primary from secondary hypertension, and how to deploy both lifestyle and pharmacological interventions.

Key Concepts

• The Three Pillars of ASCVD Risk: Cardiovascular and cerebrovascular diseases are driven by area-under-the-curve exposure to the blood vessel lining (endothelium). Smoking causes a chemical disruption to the endothelium, hypertension causes a mechanical disruption, and apoB represents the concentration of lipoproteins that penetrate that disrupted endothelium to trigger plaque formation.
• Physiology of Systole and Diastole: Blood pressure measures systemic arterial pressure (excluding pulmonary pressure) in millimeters of mercury (mmHg), historically based on how many millimeters pressure can raise a column of mercury in a manometer. Systole is the contraction phase when the left ventricle pumps blood against systemic resistance through the aortic valve into the ascending aorta and main systemic arteries (common carotid, subclavian, and innominate arteries); all organs except the heart receive their blood supply during systole. Diastole is the relaxation phase when the ventricle fills via the left atrium; the heart muscle itself is perfused during diastole, and the arteries maintain a tonic pressure greater than zero.
• Clinical Categories of Blood Pressure: Updated in 2017 following the SPRINT trial, clinical guidelines define Normal as systolic <120 mmHg AND diastolic <80 mmHg; Elevated as systolic 120–129 mmHg AND diastolic <80 mmHg; Stage 1 Hypertension as systolic 130–139 mmHg OR diastolic 80–89 mmHg (meaning 120/83 mmHg is Stage 1 hypertension); and Stage 2 Hypertension as systolic ≥140 mmHg OR diastolic ≥90 mmHg.
• Evidence for Intensive Blood Pressure Lowering (SPRINT and STEP Trials): The 2015 SPRINT trial randomized nearly 10,000 non-diabetic, high-risk patients (mean baseline ~140/78 mmHg) to an intensive target (<120 mmHg systolic, achieving a 121.4 mmHg average at 1 year) or standard target (<140 mmHg systolic, achieving 136.2 mmHg). Measurements required sitting quietly for 5 minutes (no talking, back supported, legs uncrossed) followed by three automated cuff readings at 5-minute intervals (15 minutes total) averaged together. Though Attia believes it was planned for five years (noting he could be mistaken), it was halted early at just over 3 years due to overwhelming benefit: the intensive group saw a 25% relative risk reduction in primary composite cardiovascular outcomes (Attia verbatim states a hazard ratio of 0.075, with an ~0.54% 1-year absolute risk difference and what he believes is an unadjusted 1.6% lower total event rate at 3 years), a 2x reduction in CVD death, and a 27% relative reduction (1.2% absolute reduction) in all-cause mortality. Attia caveats that reductions seen in kidney deaths, accidental deaths, suicide, and homicide might not pan out in a 100,000-person study. The 2021 STEP trial of ~8,500 Chinese adults aged 60–80 (including diabetics, mean baseline 146/83 mmHg) over just over 3 years compared targets of 110–130 mmHg vs. 130–150 mmHg systolic (achieving 76.4 vs. 79.2 mmHg diastolic), finding a 26% relative reduction in composite CVD events and a 28% reduction in CVD death (~1% absolute annual reduction), though no difference in all-cause mortality.
• Hypotension and the Danger of Going Too Low: Unlike apoB, where you cannot go too low, blood pressure can be driven dangerously low. While <90/60 mmHg is generally considered low, hypotension is defined clinically by symptoms—orthostasis (lightheadedness upon standing), dizziness, syncope (fainting), poor concentration, and blurred vision—rather than a strict number. Some individuals thrive at 100/70 mmHg, whereas medicating others to that level causes fainting; Stenson notes an anecdote where Attia himself fainted while dehydrated after a flight, hitting a nightstand and requiring stitches on his head.
• Epidemiology and Demographic Risk: Stage 1 and 2 hypertension affect 46% of US adults. Prevalence rises sharply with age: ~30% of men and just under 20% of women aged 20–44; 50% of men and 44% of women aged 45–55; and >80% of both sexes aged ≥75. By race/ethnicity (men/women), prevalence is highest in African Americans (59%/56%), followed by Non-Hispanic Whites (47%/41%), Non-Hispanic Asians (45%/36%), and Hispanics (44%/42%).
• Multi-Organ Damage (Heart, Kidneys, and Brain): 1960s Framingham data showed lowering BP below 140/90 mmHg reduced stroke by 35–40%, overall CVD by 50%, heart failure by 64%, and myocardial infarction by 15–25%. Meta-analyses of adults aged 40–70 show every 20 mmHg systolic and 10 mmHg diastolic increase above 120/80 mmHg doubles the risk of fatal vascular disease. For the brain, the SPRINT MIND trial (>9,000 subjects) showed intensive BP lowering reduced dementia by 16% relatively (0.6% absolute risk reduction). For the kidneys—which weigh 1–2% of body weight but receive 20–25% of cardiac output—high BP and elevated glucose act as a "double whammy" that destroys microvascular filtration. Standard labs flag an eGFR ≥60 mL/min as normal, but Attia notes 60 mL/min is only normal for a 75-year-old; a 50-year-old should be near 100 mL/min, and a reading of 60 hints at underlying hypertension.
• Sources of Measurement Error and Cuff Inaccuracies: Because hypertension is a symptomless "silent killer," accurate measurement is critical, yet minor errors drastically skew readings: unsupported back/feet (+5 to 10 mmHg), crossed legs (+5 to 8 mmHg), skipping a 3-to-5-minute quiet rest (+10 to 20 mmHg; Attia's own BP drops 10 points after waiting 5 minutes), talking (+10 to 15 mmHg), acute pain (+10 to 30 mmHg), a full bladder (+10 to 15 mmHg), wrong cuff size, or placing the cuff over clothing. Arm height relative to the heart alters readings by ~2 mmHg per inch (higher when below the heart, lower when above). Furthermore, Attia found across three doctor-verified comparisons that even high-end automated cuffs overestimate his systolic BP by 10 to 15 mmHg compared to manual auscultation; he hedges that he does not know why and suspects individual variation, hypothesizing via Occam's razor that automated cuffs measure mean arterial pressure and algorithmically impute systolic and diastolic values.
• Daily Variations, Stress, and Exercise Responses: Healthy blood pressure exhibits a diurnal rhythm, dipping 10 to 20% during sleep due to horizontal posture and parasympathetic/vagal tone (measured via 24-hour ambulatory monitors inflating every 15–30 minutes). Transient stress or irritability can push Attia's own systolic BP >140 mmHg. During exercise (like a VO2 max test or heavy squats/deadlifts with a Valsalva maneuver), systolic BP normally rises to 180–200+ mmHg, but diastolic BP should stay flat or decrease due to arteriolar vasodilation; a rising diastolic pressure during exercise is abnormal.
• Primary vs. Secondary Hypertension: Primary ("essential") hypertension accounts for ~90% of cases and has no single identifiable cause, driven instead by lifestyle and genetics (both of Attia's parents have hypertension, showing genetics can override lifestyle). Secondary hypertension accounts for ~10% of cases and stems from correctable conditions like renal artery stenosis, intrinsic kidney disease, thyroid disorders, hyperaldosteronism, or pheochromocytoma (an adrenal tumor). Red flags include onset at a young age (e.g., 30 without obesity or family history), rapid onset, extreme readings (>180 mmHg systolic), or medication resistance. Attia recounts a fit athlete friend with 180–190/120 mmHg morning BP whose doctor refused to test urine metanephrines; Attia spotted an uncalled adrenal nodule on the friend's prior chest MRI, and surgical removal completely normalized his BP.
• Lifestyle Mechanisms (Sodium, Insulin Resistance, and Sleep): Attia estimates up to 50% of hypertensive patients could manage their condition via lifestyle alone (hedging that he doesn't know the exact percentage). While reducing sodium from the US average (3.5–4.5 g/day) to 1,500 mg/day lowers systolic BP by 5 to 6 mmHg in salt-sensitive groups (African Americans, older adults, and those with hypertension, metabolic syndrome, diabetes, or CKD), an Institute of Medicine meta-analysis found restricting sodium to 1,500 mg/day is associated with worse health outcomes and increased all-cause mortality. Rick Johnson hypothesizes salt sensitivity is mitigated by drinking water before or with salty meals to prevent serum sodium spikes. Additionally, insulin resistance, high homocysteine, and poor renal function elevate ADMA and SDMA, which inhibit nitric oxide synthase and reduce vasodilating nitric oxide (NO). Finally, sleeping <5 hours or >10 hours per night (often a proxy for fragmented sleep or chronic illness) is associated with up to a 40% increased risk of hypertension.
• Pharmacology and First-Line Drug Classes: While hedging that he does not consider himself at all an expert in treating hypertension, Attia shares his practice's internal white paper findings on the four first-line drug classes (beta- and alpha-blockers are no longer first-line): ACE inhibitors, ARBs, Thiazide diuretics, and Calcium channel blockers (CCBs). All four lower systolic BP by ~12 to 15 mmHg and diastolic by ~9 to 11 mmHg (often at half the max dose for ACE inhibitors). Attia favors ARBs first-line because they match or slightly beat ACE inhibitors in efficacy without side effects like chronic cough (though insurance favors cheaper ACE inhibitors), reserving thiazides and CCBs as add-ons due to higher side effects. Clinical nuances dictate avoiding CCBs in heart failure with reduced ejection fraction; avoiding ACE inhibitors and ARBs in pregnancy, renal artery stenosis, or angioedema history; avoiding thiazides in gout, hyperlipidemia, or type 2 diabetes; and favoring thiazides or CCBs in African American patients for superior event reduction (while viewing both ACE inhibitors and ARBs as reasonable for diabetes/CKD despite textbook dogma favoring ACE inhibitors).

Quotes

• At 0:11:38 - "If blood pressure is both less systolically than 120 and diastolically 80, that's considered normal. So, 119 over 79, normal. 121 over 79, technically not normal." - Defining the strict thresholds established by the 2017 clinical guidelines.
• At 0:18:34 - "What I think really caught people off guard, in a pleasant way, was that all-cause mortality was also reduced 27%. And it was like a 1.2% absolute risk reduction." - Explaining the dramatic mortality benefits of intensive blood pressure lowering (<120 mmHg systolic) in the SPRINT trial.
• At 0:21:20 - "Elevated blood pressure, hypertension, is a mechanical disruption to the endothelium. Smoking is a chemical disruption to the endothelium. And of course, apoB is the concentration of the lipoprotein that itself goes through that disrupted endothelium and then causes the pathologic sequence of events that we're very familiar with." - Framing how the three major pillars of cardiovascular risk interact to cause vascular disease.
• At 0:23:20 - "The other thing you have to think about is with apoB, you can't go too low. With blood pressure, you can go too low." - Highlighting why clinicians must be cautious about over-medicating borderline blood pressure and inducing symptomatic hypotension.
• At 0:23:36 - "We don't even entertain looking at your blood pressure unless we've seen two weeks of checking it two to three times a day under perfect conditions." - Emphasizing why single in-office blood pressure measurements are insufficient for diagnosing or treating hypertension.
• At 0:29:17 - "If your blood pressure is 140 over 90 as opposed to 120 over 80, you've doubled your risk of death—not incidence, death—from stroke, heart disease, or vascular disease." - Citing meta-analysis data for 40-to-70-year-olds showing that every 20/10 mmHg increase above 120/80 doubles fatal vascular risk.
• At 0:32:51 - "The kidneys are tiny little things, right? They weigh like 1 to 2% of your total body weight, and yet they're receiving 20 to 25% of your cardiac output with each pump of the heart." - Explaining the anatomical reason why the kidneys are exceptionally vulnerable to high blood pressure.
• At 0:35:28 - "If you care about your brain, if you care about your heart, and if you care about your kidneys, you need low blood pressure. I think we can say that as confidently as we can say almost anything in medicine." - Summarizing the comprehensive organ protection provided by maintaining normal blood pressure.
• At 0:42:22 - "For every inch that your arm is below your heart, you'll see about an average of nearly 2 millimeters of mercury per inch. And similarly, it's about 2 millimeters of mercury per inch for every inch your arm is above your heart." - Detailing how minor positioning errors during measurement can significantly skew blood pressure readings.
• At 0:58:31 - "Lifestyle is a far greater hammer on blood pressure than it is on lipids." - Contrasting the high responsiveness of blood pressure to behavioral changes against the difficulty of lowering apoB through diet alone.
• At 0:59:52 - "For every kilo of weight loss, you're going to see a little more than 1 millimeter of mercury reduction in systolic, and almost 1 millimeter reduction in diastolic." - Quantifying the direct, linear blood pressure benefits of losing weight through caloric, dietary, or time restriction.
• At 1:15:15 - "I view it as sort of catastrophic when I see people, and I see them all the time, who are biohacking their way into obscurity, all the while ignoring their blood pressure." - Warning listeners not to neglect foundational health metrics in favor of trendy longevity hacks.

Takeaways

• Execute a 2-Week Home Monitoring Protocol: Never rely on a single clinic reading. Measure your blood pressure 2 to 3 times a day for two weeks using a properly fitted cuff on bare skin after sitting quietly for 3 to 5 minutes (no talking or phone use), with an empty bladder, back supported, feet flat and uncrossed, and the cuff positioned exactly at heart level.
• Verify Automated Cuffs Against Manual Readings: Because automated cuffs can algorithmically overestimate systolic pressure by 10 to 15 mmHg in certain individuals, bring your home cuff to your doctor's office to calibrate it against a manual auscultation reading (inflating 30 mmHg past pulse disappearance over the brachial artery and listening for the first thud of systole and sound disappearance of diastole).
• Request Cystatin C to Monitor Kidney Health: Ask your physician to measure Cystatin C rather than relying solely on standard creatinine-based eGFR, and evaluate your results against age-appropriate norms (e.g., aiming for ~100 mL/min at age 50 rather than accepting the standard lab cutoff of ≥60 mL/min).
• Leverage Weight Loss and Exercise Before Jumping to Medication for Borderline Readings: If your 2-week average is slightly elevated (e.g., 123/79 mmHg), prioritize lifestyle changes: every 1 kg of weight loss drops systolic BP by >1 mmHg and diastolic by nearly 1 mmHg, while 90 to 150 minutes/week of Zone 2 endurance training (65–75% max heart rate) lowers systolic BP by up to 8 mmHg and diastolic by at least 5 mmHg (supplemented by dynamic resistance training at 50–100% 1RM for ~2/3 mmHg reductions or isometric training for ~6/3 mmHg reductions).
• Optimize Hydration and Whole-Food Potassium Over Extreme Sodium Restriction: Avoid restricting sodium down to 1,500 mg/day due to associations with worse overall health outcomes; instead, drink water before or during salty meals to blunt serum sodium spikes and increase dietary potassium through whole foods like potatoes and bananas (avoiding dangerous potassium supplements).
• Investigate Secondary Causes if Red Flags Appear: If you experience sudden-onset hypertension, readings >180 mmHg systolic, onset at a young age without family history or obesity, or resistance to medications, push for diagnostic workups (such as imaging or urine metanephrine testing) to rule out secondary causes like pheochromocytoma or renal artery stenosis.
• Tailor First-Line Pharmacology to Your Medical Profile: If lifestyle interventions are insufficient, discuss starting an ARB as a preferred first-line agent (to avoid the chronic cough of ACE inhibitors), or select specific classes based on your profile—such as thiazide diuretics or calcium channel blockers for African American patients, while avoiding thiazides if you have gout or diabetes and avoiding CCBs if you have heart failure with reduced ejection fraction.